Arrow Electronics heads into September with a clear tension at its core: the stock fell sharply on its August earnings print, yet short sellers have spent the subsequent weeks covering — a divergence that makes the positioning story more nuanced than the price action alone suggests.
The most striking feature of the lending market is how little pressure there is. Short interest has fallen 19% over the past month to just 2.3% of free float — a low enough level that it barely registers as a bearish signal. Borrow costs confirm the same story: cost-to-borrow dropped to 0.19%, down nearly 80% on the week, after briefly touching 0.93% in late August. Availability is at 7,773% — meaning there are roughly 77 shares available to borrow for every one currently shorted — well into loose territory and close to the highest level of the past year. The ORTEX short score has edged lower to 31.4, ticking down all week. There is no squeeze pressure here, no sign of a building short thesis.
Options positioning adds a modest wrinkle. The put/call ratio has drifted higher to 0.66, about 1.1 standard deviations above its 20-day average of 0.56. That is not an extreme reading — the 52-week high sits at 2.19 — but the move does suggest that since late August, options traders have quietly added more downside protection than usual. Notably, the PCR spent most of August in the 0.46–0.49 range before stepping up in the final week. That shift tracks with the post-earnings slide, with some investors paying to hedge rather than sell outright.
The Street is split. Wells Fargo kept its Underweight on August 7, raising its target to $200 while Truist Securities maintained Buy but trimmed from $260 to $250 after the same earnings release — a signal that even bulls acknowledge the print disappointed. The consensus mean target of $235 sits about 14% above the current price of $205.98, which provides a reasonable implied return for those who hold the constructive view. B of A upgraded to Neutral in May with a $233 target, suggesting the middle of the analyst community sees limited near-term upside after the stock's run earlier in the year. The valuation case remains inexpensive in absolute terms: the trailing P/E is around 9x and EV/EBITDA near 7.1x. EPS momentum ranks in the 82nd percentile on a 30-day basis, though the 90-day reading at 62 and the 12-month forward earnings growth rank at just 22 tell a less exciting story about the pace of recovery ahead.
The August earnings reaction deserves attention. The most recent print on August 6-7 sent the stock down roughly 10% the next day and an additional 8% over the following week — a notably harsh market reaction that was worse than earlier historical episodes in the data. Avnet, the closest peer with a 73% correlation, gained 2.1% on the week while ARW rose 1.7%, a rough parity that suggests the modest recovery is sector-driven rather than company-specific. Vishay Intertechnology and nLIGHT both dropped 5-7% on the week, highlighting how divergent outcomes are across components names right now.
The institutional register is stable but worth a note. ACR Alpine Capital Research trimmed its filing stake sharply — from 6.7% to 2.9% as of its August 5 disclosure — the most notable movement among the 13D/G filers recently. All registered holders are passive 13G filers; there is no activist on the register. The disclosure caveat applies: stakes are as-last-disclosed and holders dropping below 5% may exit without a further filing. Insider data from EDGAR is stale beyond the 90-day threshold, so no current executive-level signal is available to supplement the picture.
With the next earnings date not until November 6, what to watch between now and then is whether the put/call ratio retreats back toward its August midpoint or continues drifting higher — that gap between options caution and a genuinely uncrowded short book will tell the story of whether the market is hedging a recovery or quietly pricing in another difficult quarter.
See the live data behind this article on ORTEX.
Open ARW on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
